Selected estrogen receptor 1 and androgen receptor gene polymorphisms in relation to risk of breast cancer and fibrocystic breast conditions among Chinese women

Cancer Epidemiology

Volumn 35, Issue 1, 2011, Pages 48-55

  Sakoda, Lori C ^a,b   Blackston, Christie R ^d   Doherty, Jennifer A ^a   Ray, Roberta M ^a   Lin, Ming Gang ^a   Gao, Dao Li ^e   Stalsberg, Helge ^f,g   Feng, Ziding ^a   Thomas, David B ^a,b   Chen, Chu ^a,b,c  

^a USA   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^d Fudan University ^*  (United States)

^e FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^f UNIVERSITY OF TROMSØ   (Norway)

^g UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

Author keywords

Androgen receptor; Breast neoplasm; Chinese; Estrogen receptor alpha; Fibrocystic breast disease; Genetic polymorphism

Indexed keywords

ANDROGEN RECEPTOR; ESTROGEN RECEPTOR ALPHA;

ADULT; ARTICLE; BODY MASS; BREAST CANCER; CAG REPEAT; CANCER RISK; CELL PROLIFERATION; CHINESE; CONTROLLED STUDY; DNA POLYMORPHISM; FEMALE; FIBROCYSTIC BREAST DISEASE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC CODE; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; HISTOPATHOLOGY; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MENOPAUSE; PRIORITY JOURNAL; RECEPTOR GENE;

ADULT; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; BREAST NEOPLASMS; CASE-CONTROL STUDIES; CYST FLUID; ESTROGEN RECEPTOR ALPHA; FEMALE; FIBROCYSTIC BREAST DISEASE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MIDDLE AGED; POLYMORPHISM, GENETIC; RECEPTORS, ANDROGEN; RISK FACTORS;

EID: 79951556163     PISSN: 18777821     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canep.2010.08.005     Document Type: Article

References (64)

1. Gao X., Loggie B.W., Nawaz Z. The roles of sex steroid receptor coregulators in cancer. Mol Cancer 2002, 1:7.
2. Wedren S., Lovmar L., Humphreys K., Magnusson C., Melhus H., Syvanen A.C., et al. Oestrogen receptor alpha gene haplotype and postmenopausal breast cancer risk: a case control study. Breast Cancer Res 2004, 6:R437-R449.
3. Modugno F., Zmuda J.M., Potter D., Cai C., Ziv E., Cummings S.R., et al. Estrogen metabolizing polymorphisms and breast cancer risk among older white women. Breast Cancer Res Treat 2005, 93:261-270.
4. Onland-Moret N.C., van Gils C.H., Roest M., Grobbee D.E., Peeters P.H. The estrogen receptor alpha gene and breast cancer risk (The Netherlands). Cancer Causes Control 2005, 16:1195-1202.
5. Kjaergaard A.D., Ellervik C., Tybjaerg-Hansen A., Axelsson C.K., Gronholdt M.L., Grande P., et al. Estrogen receptor alpha polymorphism and risk of cardiovascular disease, cancer, and hip fracture: cross-sectional, cohort, and case-control studies and a meta-analysis. Circulation 2007, 115:861-871.
6. Slattery M.L., Sweeney C., Herrick J., Wolff R., Baumgartner K., Giuliano A., et al. ESR1, AR, body size, and breast cancer risk in Hispanic and non-Hispanic white women living in the Southwestern United States. Breast Cancer Res Treat 2007, 105:327-335.
7. Gonzalez-Mancha R., Galan J.J., Crespo C., Iglesias Perez L., Gonzalez-Perez A., Moron F.J., et al. Analysis of the ERalpha germline PvuII marker in breast cancer risk. Med Sci Monit 2008, 14:CR136-CR143.
8. Gonzalez-Zuloeta Ladd A.M., Vasquez A.A., Rivadeneira F., Siemes C., Hofman A., Stricker B.H., et al. Estrogen receptor alpha polymorphisms and postmenopausal breast cancer risk. Breast Cancer Res Treat 2008, 107:415-419.
9. Sonestedt E., Ivarsson M.I., Harlid S., Ericson U., Gullberg B., Carlson J., et al. The protective association of high plasma enterolactone with breast cancer is reasonably robust in women with polymorphisms in the estrogen receptor alpha and beta genes. J Nutr 2009, 139:993-1001.
10. Dunning A.M., Healey C.S., Baynes C., Maia A.T., Scollen S., Vega A., et al. Association of ESR1 gene tagging SNPs with breast cancer risk. Hum Mol Genet 2009, 18:1131-1139.
11. MARIE-GENICA Consortium on Genetic Susceptibility for Menopausal Hormone Therapy Related Breast Cancer Risk Polymorphisms in genes of the steroid receptor superfamily modify postmenopausal breast cancer risk associated with menopausal hormone therapy. Int J Cancer 2010, 126:2935-2946.
12. Cai Q., Shu X.O., Jin F., Dai Q., Wen W., Cheng J.R., et al. Genetic polymorphisms in the estrogen receptor alpha gene and risk of breast cancer: results from the Shanghai Breast Cancer Study. Cancer Epidemiol Biomarkers Prev 2003, 12:853-859.
13. Shin A., Kang D., Nishio H., Lee M.J., Park S.K., Kim S.U., et al. Estrogen receptor alpha gene polymorphisms and breast cancer risk. Breast Cancer Res Treat 2003, 80:127-131.
14. Lu X., Li B., Wei J.M., Hua B. The XbaI and PvuII gene polymorphisms of the estrogen receptor alpha gene in Chinese women with breast cancer. Chung-Hua Wai Ko Tsa Chih 2005, 43:290-293.
15. Shen Y., Li D.K., Wu J., Zhang Z., Gao E. Joint effects of the CYP1A1 MspI, ERalpha PvuII, and ERalpha XbaI polymorphisms on the risk of breast cancer: results from a population-based case-control study in Shanghai, China. Cancer Epidemiol Biomarkers Prev 2006, 15:342-347.
16. Sangrajrang S., Sato Y., Sakamoto H., Ohnami S., Laird N.M., Khuhaprema T., et al. Genetic polymorphisms of estrogen metabolizing enzyme and breast cancer risk in Thai women. Int J Cancer 2009, 125:837-843.
17. Li N., Dong J., Hu Z., Shen H., Dai M. Potentially functional polymorphisms in ESR1 and breast cancer risk: a meta-analysis. Breast Cancer Res Treat 2010, 121:177-184.
18. Hu Z., Song C.G., Lu J.S., Luo J.M., Shen Z.Z., Huang W., et al. A multigenic study on breast cancer risk associated with genetic polymorphisms of ER Alpha, COMT and CYP19 gene in BRCA1/BRCA2 negative Shanghai women with early onset breast cancer or affected relatives. J Cancer Res Clin Oncol 2007, 133:969-978.
19. Nicolas Diaz-Chico B., German Rodriguez F., Gonzalez A., Ramirez R., Bilbao C., Cabrera de Leon A., et al. Androgens and androgen receptors in breast cancer. J Steroid Biochem Mol Biol 2007, 105:1-15.
20. Liede A., Zhang W., De Leon Matsuda M.L., Tan A., Narod S.A. Androgen receptor gene polymorphism and breast cancer susceptibility in the Philippines. Cancer Epidemiol Biomarkers Prev 2003, 12:848-852.
21. Elhaji Y.A., Gottlieb B., Lumbroso R., Beitel L.K., Foulkes W.D., Pinsky L., et al. The polymorphic CAG repeat of the androgen receptor gene: a potential role in breast cancer in women over 40. Breast Cancer Res Treat 2001, 70:109-116.
22. Giguere Y., Dewailly E., Brisson J., Ayotte P., Laflamme N., Demers A., et al. Short polyglutamine tracts in the androgen receptor are protective against breast cancer in the general population. Cancer Res 2001, 61:5869-5874.
23. Rebbeck T.R., Kantoff P.N., Krithivas K., Neuhausen S., Blackwood M.A., Godwin A.K., et al. Modification of BRCA1-associated breast cancer risk by the polymorphic androgen-receptor CAG repeat. Am J Hum Genet 1999, 64:1371-1377.
24. Anghel A., Raica M., Marian C., Ursoniu S., Mitrasca O. Combined profile of the tandem repeats CAG, TA and CA of the androgen and estrogen receptor genes in breast cancer. J Cancer Res Clin Oncol 2006, 132:727-733.
25. Gonzalez A., Javier Dorta F., Rodriguez G., Brito B., Rodriguez M.A., Cabrera A., et al. Increased risk of breast cancer in women bearing a combination of large CAG and GGN repeats in the exon 1 of the androgen receptor gene. Eur J Cancer 2007, 43:2373-2380.
26. Spurdle A.B., Dite G.S., Chen X., Mayne C.J., Southey M.C., Batten L.E., et al. Androgen receptor exon 1 CAG repeat length and breast cancer in women before age forty years. J Natl Cancer Inst 1999, 91:961-966.
27. Dunning A.M., McBride S., Gregory J., Durocher F., Foster N.A., Healey C.S., et al. No association between androgen or vitamin D receptor gene polymorphisms and risk of breast cancer. Carcinogenesis 1999, 20:2131-2135.
28. Kadouri L., Easton D.F., Edwards S., Hubert A., Kote-Jarai Z., Glaser B., et al. CAG and GGC repeat polymorphisms in the androgen receptor gene and breast cancer susceptibility in BRCA1/2 carriers and non-carriers. Br J Cancer 2001, 85:36-40.
29. Haiman C.A., Brown M., Hankinson S.E., Spiegelman D., Colditz G.A., Willett W.C., et al. The androgen receptor CAG repeat polymorphism and risk of breast cancer in the Nurses' Health Study. Cancer Res 2002, 62:1045-1049.
30. Suter N.M., Malone K.E., Daling J.R., Doody D.R., Ostrander E.A. Androgen receptor (CAG)(n) and (GGC)(n) polymorphisms and breast cancer risk in a population-based case-control study of young women. Cancer Epidemiol Biomarkers Prev 2003, 12:127-135.
31. Wang W., John E.M., Ingles S.A. Androgen receptor and prostate-specific antigen gene polymorphisms and breast cancer in African-American women. Cancer Epidemiol Biomarkers Prev 2005, 14:2990-2994.
32. Cox D.G., Blanche H., Pearce C.L., Calle E.E., Colditz G.A., Pike M.C., et al. A comprehensive analysis of the androgen receptor gene and risk of breast cancer: results from the National Cancer Institute Breast and Prostate Cancer Cohort Consortium (BPC3). Breast Cancer Res 2006, 8:R54.
33. Spurdle A.B., Antoniou A.C., Duffy D.L., Pandeya N., Kelemen L., Chen X., et al. The androgen receptor CAG repeat polymorphism and modification of breast cancer risk in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res 2005, 7:R176-R183.
34. Iobagiu C., Lambert C., Normand M., Genin C. Microsatellite profile in hormonal receptor genes associated with breast cancer. Breast Cancer Res Treat 2006, 95:153-159.
35. Wedren S., Magnusson C., Humphreys K., Melhus H., Kindmark A., Stiger F., et al. Associations between androgen and Vitamin D receptor microsatellites and postmenopausal breast cancer. Cancer Epidemiol Biomarkers Prev 2007, 16:1775-1783.
36. Wu M.H., Chou Y.C., Yu C.P., Yang T., You S.L., Chen C.J., et al. Androgen receptor gene CAG repeats, estrogen exposure status, and breast cancer susceptibility. Eur J Cancer Prev 2008, 17:317-322.
37. Jakubowska A., Gronwald J., Menkiszak J., Gorski B., Huzarski T., Byrski T., et al. BRCA1-associated breast and ovarian cancer risks in Poland: no association with commonly studied polymorphisms. Breast Cancer Res Treat 2010, 119:201-211.
38. Hao Y, Montiel R, Li B, Huang E, Zeng L, Huang Y. Association between androgen receptor gene CAG repeat polymorphism and breast cancer risk: a meta-analysis. Breast Cancer Res Treat 2010; in press.
39. Hietala M., Sandberg T., Borg A., Olsson H., Jernstrom H. Testosterone levels in relation to oral contraceptive use and the androgen receptor CAG and GGC length polymorphisms in healthy young women. Hum Reprod 2007, 22:83-91.
40. Dupont W.D., Page D.L. Risk factors for breast cancer in women with proliferative breast disease. N Engl J Med 1985, 312:146-151.
41. Carter C.L., Corle D.K., Micozzi M.S., Schatzkin A., Taylor P.R. A prospective study of the development of breast cancer in 16,692 women with benign breast disease. Am J Epidemiol 1988, 128:467-477.
42. London S.J., Connolly J.L., Schnitt S.J., Colditz G.A. A prospective study of benign breast disease and the risk of breast cancer. JAMA 1992, 267:941-944.
43. Gallicchio L., Berndt S.I., McSorley M.A., Newschaffer C.J., Thuita L.W., Argani P., et al. Polymorphisms in estrogen-metabolizing and estrogen receptor genes and the risk of developing breast cancer among a cohort of women with benign breast disease. BMC Cancer 2006, 6:173.
44. De Abreu F.B., Pirolo L.J., Canevari Rde A., Rosa F.E., Moraes Neto F.A., Caldeira J.R., et al. Shorter CAG repeat in the AR gene is associated with atypical hyperplasia and breast carcinoma. Anticancer Res 2007, 27:1199-1205.
45. Sakoda L.C., Blackston C.R., Xue K., Doherty J.A., Ray R.M., Lin M.G., et al. Glutathione S-transferase M1 and P1 polymorphisms and risk of breast cancer and fibrocystic breast conditions in Chinese women. Breast Cancer Res Treat 2008, 109:143-155.
46. Thomas D.B., Gao D.L., Self S.G., Allison C.J., Tao Y., Mahloch J., et al. Randomized trial of breast self-examination in Shanghai: methodology and preliminary results. J Natl Cancer Inst 1997, 89:355-365.
47. Thomas D.B., Gao D.L., Ray R.M., Wang W.W., Allison C.J., Chen F.L., et al. Randomized trial of breast self-examination in Shanghai: final results. J Natl Cancer Inst 2002, 94:1445-1457.
48. Aaman T.B., Stalsberg H., Thomas D.B. Extratumoral breast tissue in breast cancer patients: a multinational study of variations with age and country of residence in low- and high-risk countries. WHO Collaborative Study of Neoplasia and Steroid Contraceptives. Int J Cancer 1997, 71:333-339.
49. Li W., Ray R.M., Lampe J.W., Lin M.G., Gao D.L., Wu C., et al. Dietary and other risk factors in women having fibrocystic breast conditions with and without concurrent breast cancer: a nested case-control study in Shanghai, China. Int J Cancer 2005, 115:981-993.
50. Miller S.A., Dykes D.D., Polesky H.F. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988, 16:1215.
51. Bell G.I., Karam J.H., Rutter W.J. Polymorphic DNA region adjacent to the 5' end of the human insulin gene. Proc Natl Acad Sci USA 1981, 78:5759-5763.
52. Modugno F., Weissfeld J.L., Trump D.L., Zmuda J.M., Shea P., Cauley J.A., et al. Allelic variants of aromatase and the androgen and estrogen receptors: toward a multigenic model of prostate cancer risk. Clin Cancer Res 2001, 7:3092-6096.
53. Tsai Y.C., Simoneau A.R., Spruck C.H., Nichols P.W., Steven K., Buckley J.D., et al. Mosaicism in human epithelium: macroscopic monoclonal patches cover the urothelium. J Urol 1995, 153:1697-1700.
54. Hsing A.W., Gao Y.T., Wu G., Wang X., Deng J., Chen Y.L., et al. Polymorphic CAG and GGN repeat lengths in the androgen receptor gene and prostate cancer risk: a population-based case-control study in China. Cancer Res 2000, 60:5111-5116.
55. Irvine R.A., Yu M.C., Ross R.K., Coetzee G.A. The CAG and GGC microsatellites of the androgen receptor gene are in linkage disequilibrium in men with prostate cancer. Cancer Res 1995, 55:1937-1940.
56. Zheng W., Long J., Gao Y.T., Li C., Zheng Y., Xiang Y.B., et al. Genome-wide association study identifies a new breast cancer susceptibility locus at 6q25.1. Nat Genet 2009, 41:324-328.
57. Ding S.L., Yu J.C., Chen S.T., Hsu G.C., Hsu H.M., Ho J.Y., et al. Diverse associations between ESR1 polymorphism and breast cancer development and progression. Clin Cancer Res 2010, 16:3473-3484.
58. Kristiansen M., Langerod A., Knudsen G.P., Weber B.L., Borresen-Dale A.L., Orstavik K.H. High frequency of skewed X inactivation in young breast cancer patients. J Med Genet 2002, 39:30-33.
59. Kristiansen M., Knudsen G.P., Maguire P., Margolin S., Pedersen J., Lindblom A., et al. High incidence of skewed X chromosome inactivation in young patients with familial non-BRCA1/BRCA2 breast cancer. J Med Genet 2005, 42:877-880.
60. Chamberlain N.L., Driver E.D., Miesfeld R.L. The length and location of CAG trinucleotide repeats in the androgen receptor N-terminal domain affect transactivation function. Nucleic Acids Res 1994, 22:3181-3186.
61. Westberg L., Baghaei F., Rosmond R., Hellstrand M., Landen M., Jansson M., et al. Polymorphisms of the androgen receptor gene and the estrogen receptor beta gene are associated with androgen levels in women. J Clin Endocrinol Metab 2001, 86:2562-2568.
62. Brum I.S., Spritzer P.M., Paris F., Maturana M.A., Audran F., Sultan C. Association between androgen receptor gene CAG repeat polymorphism and plasma testosterone levels in postmenopausal women. J Soc Gynecol Invest 2005, 12:135-141.
63. Eliassen A.H., Hankinson S.E. Endogenous hormone levels and risk of breast, endometrial and ovarian cancers: prospective studies. Adv Exp Med Biol 2008, 630:148-165.
64. Suter N.M., Ray R.M., Hu Y.W., Lin M.G., Porter P., Gao D.L., et al. BRCA1 and BRCA2 mutations in women from Shanghai China. Cancer Epidemiol Biomarkers Prev 2004, 13:181-189.